Kevin Starr

Co-Founding Partner at Third Rock Ventures · Joined 2007

View Live Interactive Profile →

Biography

Kevin Starr co-founded Third Rock Ventures in 2007 alongside two other former Millennium Pharmaceuticals executives, after the trio grew frustrated watching big pharma and traditional VCs abandon early-stage drug discovery. Rather than simply fund existing startups, they built a genuinely different model: touring academic research facilities, workshopping breakthrough science with scientists for one to three years, then constructing companies from scratch around it - a 'Discover-Launch-Build-Transform' approach that helped create Bluebird Bio, Agios Pharmaceuticals, and Foundation Medicine. Starr focused heavily on ultra-rare and orphan diseases throughout his active years at the firm, and in 2016 he stepped back to an advisory role for Third Rock's fourth fund, a deliberate pause he attributed to the firm's team-oriented, long-term operating model no longer requiring his direct day-to-day involvement in starting new companies.

Previous Experience

Notable Investments

Bluebird Bio BLUEAgios Pharmaceuticals AGIOFoundation Medicine

Career Timeline

2006
Meets future co-founders Mark Levin and Robert Tepper at a conference, lamenting the lack of funding for disruptive biotech ideas while all three still work at Millennium Pharmaceuticals.
2007
Co-founds Third Rock Ventures in Boston, raising a $378 million debut fund within ten weeks.
2010s
Helps build Bluebird Bio, Agios, and Foundation Medicine from early scientific concepts into category-defining public companies.
2016
Steps back from active fund leadership to become an advisor for Fund IV, citing a deliberate pause on starting new companies.

Sources & References

The Org - Kevin Starr ↗Fortune ↗